Identification of aryl hydrocarbon receptor allosteric antagonists from clinically approved drugs

Documenti analoghi

• The mechanism of action and chemical synthesis of FDA newly approved drug molecules
  di: Dan‐Dan Shen, et al.
  Pubblicazione: (2024)
• In vitro and in silico investigation of FDA‐approved drugs to be repurposed against Alzheimer's disease
  di: Didem Akkaya, et al.
  Pubblicazione: (2024)
• Influence of β‐catenin signaling on neurogenesis in neuropsychiatric disorders: Anxiety and depression
  di: Rana A. El‐Kadi, et al.
  Pubblicazione: (2024)
• Design, Green Synthesis, and Biological Evaluation of Novel Triaryl‐Tethered Acryloyl Derivatives as New Generation β‐Tubulin Inhibitors for Hepatocellular Carcinoma Treatment
  di: Aamal A. Al‐Mutairi, et al.
  Pubblicazione: (2026)
• 2‐Thioxo‐3,4‐dihydropyrimidine and thiourea endowed with sulfonamide moieties as dual EGFRT790M and VEGFR‐2 inhibitors: Design, synthesis, docking, and anticancer evaluations
  di: Mohamed S. A. El‐Gaby, et al.
  Pubblicazione: (2024)